GGrantIndex
Sort

48,018 grants matching immunotherapy

Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment

$379,343
Ling Gao · Southern California Inst For Res/Educ · R01 · FY2023 · CA

Novel Approaches to Targeting Cancers Associated with VHL Mutations

$379,337
Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platform

$379,335
Tania Tali Konry · Northeastern University · R33 · FY2020 · CA

Screening and implementing universal ligands for immunoglobulins

$379,313
Valeria T Milam · Georgia Tech Research Corporation · · FY2018 · ENG

Augmentation of Immune Response to Head & Neck Squamous Cell Carcinoma via Phosp

$379,298
Ivan M Borrello · Johns Hopkins University · P50 · FY2013 · DE

Optimizing CAR T Cell Therapy

$379,293
Bruce R. Blazar · University Of Minnesota · P01 · FY2016 · CA

Cell Therapy Core

$379,270
Victor M Lemas · Johns Hopkins University · P01 · FY2019 · CA

Type I Interferon Pathway in Pancreatic Adenocarcinoma

$379,268
Serge Y Fuchs · University Of Pennsylvania · R01 · FY2020 · CA

Breaking Tolerance to Induce Tumor-Specific Cytotoxic CD4 Th1 Cells

$379,260
Adam J Adler · University Of Connecticut Sch Of Med/Dnt · R01 · FY2015 · AI

Optimizing CAR T Cell Therapy

$379,257
Bruce R. Blazar · University Of Minnesota · P01 · FY2017 · CA

SPORE in Lung Cancer

$379,250
Jill M Siegfried · University Of Pittsburgh At Pittsburgh · P50 · FY2009 · CA

A Novel Symbiotic Approach for Ovarian Cancer

$379,248
Jogender Tushir-Singh · University Of California At Davis · R01 · FY2022 · CA

Hypoxia-Perfusion Bioreactor for Stem Cell Applications

$379,228
Todd A McAdams · Resodyn Corporation · R44 · FY2009 · HL

Optimizing CAR T Cell Therapy

$379,224
Bruce R. Blazar · University Of Minnesota · P01 · FY2018 · CA

Role of KAT5 in lung cancer

$379,196
Susumu Kobayashi · Beth Israel Deaconess Medical Center · R01 · FY2024 · CA

Cellular Immunity/JC Virus/AIDS/Leukoencephalopathy

$379,170
Igor J Koralnik · Beth Israel Deaconess Medical Center · R01 · FY2006 · NS

Regulation of gamma delta T cell immunoediting by novel phosphoantigens

$379,166
Andrew J Wiemer · University Of Connecticut Storrs · R01 · FY2015 · CA

Dyslipidemia and Diabetic Retinopathy

$379,150
Julia V Busik · Michigan State University · R01 · FY2022 · EY

PET fibrin imaging of DVT and PE

$379,125
Tilo Winkler · Massachusetts General Hospital · R01 · FY2019 · HL

PET fibrin imaging of DVT and PE

$379,125
Tilo Winkler · Massachusetts General Hospital · R01 · FY2020 · HL

PET fibrin imaging of DVT and PE

$379,125
Tilo Winkler · Massachusetts General Hospital · R01 · FY2021 · HL

Stromal metabolism promotes therapeutic resistance in pancreatic cancer

$379,104
Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor · R01 · FY2024 · CA

Breaking Tolerance to Induce Tumor-Specific Cytotoxic CD4 Th1 Cells

$379,088
Adam J Adler · University Of Connecticut Sch Of Med/Dnt · R01 · FY2016 · AI

E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target

$379,055
Drew M. Pardoll · Johns Hopkins University · R01 · FY2022 · AI

The B7x pathways in the tumor microenvironment

$379,050
Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2024 · CA